Olivier L Chinot

Olivier L Chinot

UNVERIFIED PROFILE

Are you Olivier L Chinot?   Register this Author

Register author
Olivier L Chinot

Olivier L Chinot

Publications by authors named "Olivier L Chinot"

Are you Olivier L Chinot?   Register this Author

27Publications

1155Reads

26Profile Views

Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.

Eur J Cancer 2018 09 20;101:95-104. Epub 2018 Jul 20.

Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.06.029DOI Listing
September 2018

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.

Lancet Oncol 2018 09 13;19(9):1170-1179. Epub 2018 Aug 13.

The Brain and Spine Institute (ICM), Sorbonne Université, The National Institute of Health and Medical Research (INSERM), National Centre for Scientific Research (CNRS), Public Assistance-Paris Hospitals (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183036
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30362-0DOI Listing
September 2018

Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial.

Oncotarget 2018 Jan 4;9(6):6752-6762. Epub 2017 Dec 4.

Department of Oncology, Herlev University Hospital, Herlev and Gentofte Hospital, Copenhagen, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22886DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805511PMC
January 2018

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O-Methylguanine-DNA Methyltransferase Biomarker Analyses.

J Clin Oncol 2017 Jan 5;35(3):343-351. Epub 2016 Dec 5.

Timothy Cloughesy, University of California, Los Angeles; Lawrence Recht, Stanford Cancer Center, Stanford; Carlos Bais, Thomas Sandmann, Jean-Marie Bruey, Hartmut Koeppen, Bo Liu, Wendy Verret, See-Chun Phan, and David S. Shames, Genentech, South San Francisco, CA; Tom Mikkelsen, Henry Ford Hospital, Detroit, MI; Gaetano Finocchiaro, Istituto Neurologico Carlo Besta, Milan; Alba A. Brandes, Azienda Unità Sanitaria Locale-Istituto di Ricovero e Cura a Carattere Scientifico Institute of Neurologic Sciences, Bologna, Italy; Cristóbal Belda-Iniesta, Centro Integral Oncológico Clara Campal, University Hospital HM Sanchinarro, Madrid; Estela Pineda, Hospital Clinic of Barcelona; Carmen Balana, Institut Català d'Oncologia Badalona Hospital Germans Trias I Pujol, Barcelona, Spain; Olivier L. Chinot, Aix-Marseille Université Assistance Publique-Hôpitaux de Marseille, Marseille, France; David R. Macdonald, London Health Sciences Centre, London, Ontario, Canada; Manfred Westphal, University Clinic Hamburg-Eppendorf, Hamburg, Germany; Kirsten Hopkins, Bristol Haematology and Oncology Centre, Bristol, United Kingdom; and Michael Weller, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.64.7685
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.64.7685DOI Listing
January 2017

Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.

Neuro Oncol 2016 10 11;18(10):1434-41. Epub 2016 Aug 11.

University Medical Center, Heidelberg, Germany (W.W., M.B.); Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France (O.L.C.); Princess Margaret Hospital, * Toronto, Canada (W.M.); Regional Cancer Center Stockholm Gotland, Stockholm, Sweden (R.H.); Department of Radiation Sciences and Oncology, Umeå University, Umeå, Sweden (R.H.); The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK (F.S.); Saitama Medical University, Iruma, Saitama Prefecture, Japan (R.N.); F. Hoffmann-La Roche Ltd, Basel, Switzerland (C.R., Y.K.); University of California Los Angeles, Los Angeles, California (T.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now091DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035525PMC
October 2016

Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.

Neuro Oncol 2016 09 22;18(9):1313-8. Epub 2016 Mar 22.

Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France (O.L.C.); Saitama Medical University, Saitama, Japan (R.N.); Princess Margaret Hospital, Toronto, Canada (W.M.); Regional Cancer Center Stockholm Gotland, Stockholm, Sweden (R.H.); Department of Radiation Sciences and Oncology, Umeå University, Umeå, Sweden (R.H.); The Royal Marsden NHS Foundation Trust, Surrey, UK (F.S.); University of California, Los Angeles, California, USA (T.C.); F. Hoffmann-La Roche Ltd, Basel, Switzerland (J.G., C.R., L.A.); University Medical Center, Heidelberg, Germany (W.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now046DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4999000PMC
September 2016

Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.

Neuro Oncol 2016 07 24;18(7):991-1001. Epub 2016 Jan 24.

The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK (F.S.); Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France (O.L.C.); Regional Cancer Center, Stockholm-Gotland, Karolinska University Hospital, Stockholm, Sweden (R.H.); Department of Radiation Sciences and Oncology, Umeå University, Förvaltningshuset, Universitetstorget, Umeå, Sweden (R.H.); Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada (W.M.); University Medical Center and German Cancer Research Center, Heidelberg, Germany (W.W.); University of California, Los Angeles, California, USA (T.C.); Genentech Inc., South San Francisco, California, USA (S.D.); F. Hoffmann-La Roche Ltd, Basel, Switzerland (E.P., J.G.); Saitama Medical University, Saitama, Japan (R.N.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov300DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896538PMC
July 2016

Reply to T.J. Kruser et al.

J Clin Oncol 2016 Apr 16;34(11):1282-3. Epub 2016 Feb 16.

University of California, Los Angeles, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.2438DOI Listing
April 2016

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.

J Clin Oncol 2015 Sep 29;33(25):2735-44. Epub 2015 Jun 29.

Thomas Sandmann, Richard Bourgon, Congfen Li, Samir Kharbanda, Franklin Peale, Priti Hegde, Heidi S. Phillips, and Carlos Bais, Genentech, South San Francisco; Timothy Cloughesy and Albert Lai, University of California Los Angeles, Los Angeles, CA; Josep Garcia, Nicola Moore, and Lauren E. Abrey F. Hoffmann-La Roche, Basel, Switzerland; Olivier L. Chinot, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Centre Hospitalier Universitaire Timone, Marseille, France; Wolfgang Wick, University Medical Center, Heidelberg, Germany; Ryo Nishikawa, Saitama Medical University, Saitama, Japan; Warren Mason, Princess Margaret Hospital, Toronto, Ontario, Canada; Roger Henriksson, Regional Cancer Center Stockholm, Stockholm; and Umeå University, Umeå, Sweden; and Frank Saran, Royal Marsden National Health Service Foundation Trust, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.61.5005
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.61.5005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015426PMC
September 2015

Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.

Neuro Oncol 2015 Jul 9;17(7):1007-15. Epub 2015 Feb 9.

Department of Oncology, Rigshospitalet, Copenhagen, Denmark (U.L., M.M.-S.); Department of Radiology, Rigshospitalet, Copenhagen, Denmark (V.A.L.); Aix-Marseille University A.P.-H.M., Department of Neuro-Oncology, University Hospital Timone, Marseille, France (O.L.C., M.B.); Department of Clinical Oncology, The Christie Hospital N.H.S Foundation Trust, Manchester, England (C.M.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland (P.R., M.W.); Roche Diagnostics GmbH, Penzberg, Germany (O.K., K.H., A.L.); Hoffmann La Roche Pharmaceuticals, Nutley, NewJersey (K.W.); F. Hoffmann-La Roche Ltd, Basel, Switzerland (J.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654352PMC
July 2015

Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.

J Clin Oncol 2015 Jul 26;33(19):2166-75. Epub 2015 May 26.

Martin J.B. Taphoorn, Medical Center Haaglanden, the Hague, and VU University Medical Center, Amsterdam, the Netherlands; Roger Henriksson, Cancer Center Stockholm Gotland, Karolinska, Stockholm, and Umeå University, Umeå, Sweden; Andrew Bottomley, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Timothy Cloughesy, University of California, Los Angeles, Los Angeles; Christina Theodore-Oklota and Arliene Ravelo, Genentech, South San Francisco, CA; Wolfgang Wick, University Hospital of Heidelberg, Heidelberg, Germany; Warren Mason, Princess Margaret Hospital, Toronto, Ontario, Canada; Frank Saran, The Royal Marsden National Health Service Foundation Trust, Surrey, United Kingdom; Ryo Nishikawa, Saitama Medical University, Saitama, Japan; Magalie Hilton, F. Hoffmann-La Roche, Basel, Switzerland; Olivier L. Chinot, Service de Neuro-Oncologie, Aix-Marseille University, Assistance Publique- Hôpitaux de Marseille, Centre Hospitalier Universitaire Timone, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.3217DOI Listing
July 2015

Cilengitide in glioblastoma: when did it fail?

Authors:
Olivier L Chinot

Lancet Oncol 2014 Sep 19;15(10):1044-5. Epub 2014 Aug 19.

Aix-Marseille University, AP-HM, Department of Neuro-Oncology, CHU Timone, 13005 Marseille, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)70403-6DOI Listing
September 2014

Bevacizumab for newly diagnosed glioblastoma.

N Engl J Med 2014 05;370(21):2049

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1403303DOI Listing
May 2014

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

N Engl J Med 2014 Feb;370(8):709-22

From Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Service de Neuro-Oncologie, Centre Hospitaliere Universitaire Timone, Marseille (O.L.C.), UFR de Santé, Médecine et Biologie Humaine, Bobigny (A.F.C.), and Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Avicenne, Service de Neurologie, Université Paris 13 (A.F.C.), and AP-HP, Université Pierre-et-Marie-Curie, Group Hospitalier Pitié-Salpêtrière (K.H.-X.), Paris - all in France; University Hospital of Heidelberg, Department of Neurooncology, and German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany (W.W.); Princess Margaret Hospital, Toronto (W.M.), and McGill University, Montreal (P.K.) - both in Canada; Regional Cancer Center, Stockholm Gotland, Karolinska, Stockholm, and the Department of Radiation Sciences and Oncology, Umeå University, Umeå - both in Sweden (R.H.); the Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom (F.S.); Saitama Medical University, Saitama, Japan (R.N.); Oncology Institute "Ion Chiricuta," Cluj-Napoca, Romania (D.C.); Medical Oncology Department, Azienda Unità Sanitaria Locale, Bologna, Italy (A.A.B.); F. Hoffmann-La Roche, Basel, Switzerland (M.H., L.A.); and University of California, Los Angeles, Los Angeles (T.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1308345DOI Listing
February 2014

Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.

Curr Neurol Neurosci Rep 2013 May;13(5):347

Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, 264 Rue Saint Pierre, 13005, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11910-013-0347-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631110PMC
May 2013

Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.

Authors:
Olivier L Chinot

Expert Rev Anticancer Ther 2012 Nov;12(11):1413-27

Aix-Marseille University, Assistance Publique-Hopitaux de Marseille, Centre Hospitalo-Universitaire Timone, Service de Neuro-Oncologie, 13008 Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.12.128DOI Listing
November 2012

Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.

J Clin Oncol 2007 Apr;25(12):1470-5

Unité de Neuro-Oncologie, Service de Neurochirurgie, Centre Hospitalier Universitaire Timone, Assistance Publique-Hôpitaux de Marseille, and Université de la Méditérranée, Faculté de Médecine de Marseille, Marseille, France.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2006.07.4807
Publisher Site
http://dx.doi.org/10.1200/JCO.2006.07.4807DOI Listing
April 2007

Treatment of primary central nervous system lymphoma in the elderly.

Semin Oncol 2003 Dec;30(6 Suppl 19):53-7

Fédération Neurologique Mazarin (Pr JY Delattre), Groupe Hospitalier Pitié-Salpêtrire, 47 Boulevard de l'Hopital, Paris 75013, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2003.11.032DOI Listing
December 2003

Should radiotherapy be standard therapy for brain tumors in the elderly? Cons.

Authors:
Olivier L Chinot

Semin Oncol 2003 Dec;30(6 Suppl 19):68-71

Unité de Neuro-Oncologie, Service de Neurochirurgie, CHU Timone, 264, rue Saint Pierre, 13385 Marseille Cedex 05 France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2003.11.027DOI Listing
December 2003